Eczema, AtopicNCT05913791
Nutrients-fortified Egg Consumption on Eczema Condition in Individuals With Eczema
A study testing Nutrients-fortified egg and Regular egg in people with Eczema, Atopic and Inflammation; Skin, run by National University of Singapore at 1 site in Singapore.
Trial summary
The study aims to assess the effects of daily consumption of nutrients-fortified eggs on eczema condition in individuals with eczema. It is hypothesised that daily consumption of nutrients-fortified egg, which is rich in antioxidants, will improve eczema conditions in individuals with eczema as compared to consumption… Read more about this study
- Who is it for?
- Ages 21 to 59 years
- Conditions the study is for
- Eczema, Atopic, Inflammation; Skin, Eczema
- What is being tested?
- Nutrients-fortified egg and Regular egg
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 41 participants
- Where
- 1 siteSingapore
- Study dates
- 6 Mar 2023to Jan 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 59 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- English-literate and able to give informed consent in English
- Male and female subjects, aged between 21 and 59 inclusive
- Healthy individuals with no comorbidities or on regular medication
- BMI between 18.5-25 kg/m2
- Mild to moderate severity of eczema, which will also be determined using our questionnaires during screening visit
Who cannot join
- Significant change in body weight (3 kg or more) in the past 3 months
- Significant exercise pattern over the past 3 months defined as high-intensity exercise of more than 3 hours per week
- Known food allergy to eggs
- Taking dietary supplements which may impact the study results
- Had been diagnosed or with a history of gastrointestinal disorders e.g. irritable bowel syndrome, constipation, diverticulitis
- Current smokers
Show all 14Show fewer
- Consumes more than 2 alcoholic drinks per day i.e. one drink is defined as either 150ml of wine, 340ml of beer/cider or 45ml of distilled spirit
- Taking lipid-lowering and blood pressure controlling medications less than 3 years
- Pregnant or lactating women, or planning to conceive in the next 6 months
- Unwilling to stop the medication of eczema during the study, either topical creams or oral medications
- Hierarchical link (professional and familial ties) with the research team members
- Participating in another clinical study
- Having blindness in one eye or more, previously diagnosed eye diseases, or have had eye surgery
- Low quality macular pigment optical density results, determined during screening visit
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Impact of Nutrients-fortified Egg Consumption on Eczema Condition in Individuals With Eczema
The study aims to assess the effects of daily consumption of nutrients-fortified eggs on eczema condition in individuals with eczema.
It is hypothesised that daily consumption of nutrients-fortified egg, which is rich in antioxidants, will improve eczema conditions in individuals with eczema as compared to consumption of regular eggs.
Read the detailed description
Eczema refers to a group of conditions that induces inflammation of the skin. Of which, atopic dermatitis is the most common type. Eczema is common in children, and can continue to adulthood. Eczema is a chronic condition with no known cure.
Anti-inflammatory agents have been shown to protect against atopic dermatitis. Vitamin D, E and polyunsaturated fatty acids are known to confer excellent anti-inflammatory benefits.
This is a double-blinded, randomized, parallel study and all subjects will complete a 12-week study period. The study was designed based on previous research which reported that omega-3 supplementation significantly decreased blood IgE concentration (-29.0 ± 11.1, mean ± SD) compared to placebo supplementation (-7.7 ± 14.6, mean ± SD).
- Conditions
- Eczema, Atopic, Inflammation; Skin, Eczema, Hypersensitivity
- Being tested
- Nutrients-fortified egg, Regular egg
- Keywords
- Egg, Vitamin D, Vitamin E, Antioxidant, Eczema, Omega-3 long chain polyunsaturated fatty acids
- Medical subject headings
- Dermatitis, Atopic, Dermatitis, Eczema, Hypersensitivity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nutrients-fortified eggDietary supplement
Consumption of 2 cooked nutrients fortified eggs (half-boiled, hard-boiled, or steamed)
Regular eggOther
Consumption of 2 regular eggs, prepared in the same manner as nutrients-fortified egg, which serves as a placebo comparison.
| Study group | Role | What they receive |
|---|---|---|
| Nutrients-fortified egg | Experimental | Each subject will be provided with 2 nutrients-fortified eggs from N\&N Agriculture Pte Ltd to consume daily for 12 weeks. They will be instructed to consume the eggs for breakfast with the following preparation methods: hard-boiling, half-boiling and steaming. Subjects are to continue their usual diet. Receives: Dietary Supplement: Nutrients-fortified egg |
| Regular egg | Placebo comparator | Each subject will be provided with 2 regular eggs to consume daily for 12 weeks. They will be instructed to consume the eggs for breakfast with the following preparation methods: hard-boiling, half-boiling and steaming. Subjects are to continue their usual diet. Receives: Other: Regular egg |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in eczema severity using the SCORing Atopic Dermatitis (SCORAD) index
The SCORAD index is a validated composite scoring instrument designed to assess signs and symptoms of atopic dermatitis (AD). Total score ranges from 0 to 103, with higher scores indicating greater severity.
Measured: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
Change in eczema severity using the Eczema Area Severity Index (EASI)
The EASI is a validated objective instrument for assessing signs of AD. Total score ranges from 0 to 72, with higher scores indicating greater severity.
Measured: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
Change in skin quality of life assessment using the Dermatology Life Quality Index (DLQI)
The DLQI is a validated self-reported instrument assessing the self perception of impact of skin diseases on their quality of life over the previous week. Scores range from 0 to 30, with higher scores indicating greater impairment on quality of life.
Measured: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
Change in skin hydration level using corneometer
A corneometer is an electronic device used to measure hydration on the skin surface
Measured: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
Change in transepidermal water loss level using tewameter
A tewameter is an electronic device used to measure transepidermal water loss on the skin surface
Measured: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
Change in skin pH level using pH probe
A pH probe is an electronic device used to measure pH levels on the skin surface
Measured: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
Change in skin sebum level using sebumeter
A sebumeter is an electronic device used to measure sebum levels on the skin surface
Measured: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
Change in stratum corneum components via immune dot blot assay
Outermost skin surface components will be extracted to conduct dot blot assays to assess changes during intervention period
Measured: Baseline and Week 12
Change in malondialdehyde level
Malondialdehyde concentration in blood samples will be measured
Measured: Every 6 weeks (Week 0, Week 6, Week 12)
Change in 8-iso-prostaglandin F2α level
8-iso-prostaglandin F2α concentration in blood samples will be measured
Measured: Every 6 weeks (Week 0, Week 6, Week 12)
Change in interleukin-6 level
Interleukin-6 concentration in blood samples will be measured
Measured: Every 6 weeks (Week 0, Week 6, Week 12)
Change in tumor necrosis factor α
Tumor necrosis factor α concentration in blood samples will be measured
Measured: Every 6 weeks (Week 0, Week 6, Week 12)
Change in fasting blood glucose level
Fasting glucose concentration in blood samples will be measured
Measured: Every 6 weeks (Week 0, Week 6, Week 12)
Change in blood triglyceride level
Triglyceride concentration in blood samples will be measured
Measured: Every 6 weeks (Week 0, Week 6, Week 12)
Change in blood total cholesterol level
Total cholesterol levels in blood samples will be measured
Measured: Every 6 weeks (Week 0, Week 6, Week 12)
Change in blood Low-density Lipoprotein-cholesterol (LDL) level
LDL concentration in blood samples will be measured
Measured: Every 6 weeks (Week 0, Week 6, Week 12)
Change in blood High-density Lipoprotein-cholesterol (HDL) level
HDL concentration in blood samples will be measured
Measured: Every 6 weeks (Week 0, Week 6, Week 12)
Secondary outcomes (9)
Change in Blood Carotenoid levels using High Performance Liquid Chromatography (HPLC)
Carotenoid concentration in blood samples will be measured
Measured: Every 6 weeks (Week 0, Week 6, Week 12)
Change in Skin Carotenoid levels using BioPhotonic Scanner
Skin carotenoid levels will be measured from the skin surface
Measured: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
Change in Eye Carotenoid levels using Macular Pigment Scanner
Eye carotenoid levels will be measured using the Macular Pigment Scanner MPSII
Measured: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
Change in Skin Advanced Glycation End-product (AGEs)
Skin AGEs will be quantified using a noninvasive scanner
Measured: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
Change in Blood AGEs
Blood AGEs concentration in blood samples will be measured
Measured: Every 6 weeks (Week 0, Week 6, Week 12)
Change in Eye Visual Function using the NEI VFQ-25
The National Eye Institute Visual Functioning Questonnaire-25 (NEI VFQ-25) is a self-reported instrument designed to assess visual disability and health-related quality of life. The overall composite score ranges from 0 to 100, with a higher score indicating better visual function and better quality of life.
Measured: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
Change in Visual Acuity using eye chart
Visual acuity is a measure of visual function and it will be assessed by an investigator
Measured: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
Change in Contrast Sensitivity using eye chart
Contrast sensitivity is a measure of visual function and it will be assessed by an investigator
Measured: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
Change in Photostress Recovery Time using eye chart
Photostress recovery assessment is a measure of visual function and it will be assessed by an investigator
Measured: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jun 2023
- Study start6 Mar 2023
- Primary completion31 Jul 2023
- Study completionJan 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Eczema, AtopicStudies of the same condition, open and under way.
- More trials run by National University of SingaporeThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 41 participants (actual)
Sponsor and investigators
- Lead sponsor
- National University of Singapore
- Sponsor type
- University, hospital or other
- Collaborators
- Ministry of Education, Singapore
- Responsible party
- Principal investigator, Jung Eun Kim, National University of Singapore
- Investigators
- Jung Eun Kim, PhD, Principal investigator, Food Science and technology, Faculty of Science, National University of Singapore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05913791
- Sponsor's protocol ID
- S17
- Status last verified
- Nov 2023
- First submitted
- 31 Mar 2023
- Last updated
- 9 Nov 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Hard copy documents containing identifiable participant information will be stored in locked storage cabinets accessible only to members of the NUS research group. These locked storage cabinets are located in Kim lab in NUS. This lab is accessible only to Dr Kim Jung Eun, the Principal Investigator, and Dr Kim's research staff. The lab has a dual access security system, with the first entry point being an electronic lock accessible by an NUS-approved key card and the second is a physical lock. Electronic copies of the data with identifiable participant information stored electronically in NUS OneDrive. Only members of Dr Kim's lab have access to this secured folder. Access to this OneDrive folder is only granted by Dr Kim. All study samples will be de-identified prior to analysis and statistical analyses.
Publications
Ito N, Seki S, Ueda F. The Protective Role of Astaxanthin for UV-Induced Skin Deterioration in Healthy People-A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. 2018 Jun 25;10(7):817. doi: 10.3390/nu10070817.
PubMed 29941810Hu W, Li S, Li X, Chng ASM, Quek C, Chong Z, Khoo CM, Kim JE. Impact of antioxidants fortified eggs consumption on eye health in individuals with mild to moderate untreated eczema: a randomized controlled trial. Eur J Nutr. 2025 Dec 19;65(1):13. doi: 10.1007/s00394-025-03854-z.
PubMed 41417237
Study at a glance
From the registry record, last updated by the sponsor on 9 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Nutrients-fortified Egg Consumption on Eczema Condition in Individuals With Eczema
- ClinicalTrials.gov ID
- NCT05913791
- Acronym / sponsor ID
- S17
- Conditions
- Eczema, Atopic, Inflammation; Skin, Eczema, Hypersensitivity
- Keywords
- Egg, Vitamin D, Vitamin E, Antioxidant, Eczema, Omega-3 long chain polyunsaturated fatty acids
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 41 participants (actual)
- Lead sponsor
- National University of SingaporeUniversity, hospital or other
- Collaborators
- Ministry of Education, Singapore
- Study start
- 6 Mar 2023 (actual)
- Primary completion
- 31 Jul 2023 (actual)
- Study completion
- Jan 2025 (estimated)
- First posted
- 22 Jun 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study aims to assess the effects of daily consumption of nutrients-fortified eggs on eczema condition in individuals with eczema.
It is hypothesised that daily consumption of nutrients-fortified egg, which is rich in antioxidants, will improve eczema conditions in individuals with eczema as compared to consumption of regular eggs.
Detailed description
Eczema refers to a group of conditions that induces inflammation of the skin. Of which, atopic dermatitis is the most common type. Eczema is common in children, and can continue to adulthood. Eczema is a chronic condition with no known cure.
Anti-inflammatory agents have been shown to protect against atopic dermatitis. Vitamin D, E and polyunsaturated fatty acids are known to confer excellent anti-inflammatory benefits.
This is a double-blinded, randomized, parallel study and all subjects will complete a 12-week study period. The study was designed based on previous research which reported that omega-3 supplementation significantly decreased blood IgE concentration (-29.0 ± 11.1, mean ± SD) compared to placebo supplementation (-7.7 ± 14.6, mean ± SD).
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Nutrients-fortified egg | Experimental | Dietary Supplement: Nutrients-fortified eggEach subject will be provided with 2 nutrients-fortified eggs from N\&N Agriculture Pte Ltd to consume daily for 12 weeks. They will be instructed to consume the eggs for breakfast with the following preparation methods: hard-boiling, half-boiling and steaming. Subjects are to continue their usual diet. |
| Regular egg | Placebo comparator | Other: Regular eggEach subject will be provided with 2 regular eggs to consume daily for 12 weeks. They will be instructed to consume the eggs for breakfast with the following preparation methods: hard-boiling, half-boiling and steaming. Subjects are to continue their usual diet. |
Who may qualify
- Ages
- 21 to 59 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- English-literate and able to give informed consent in English
- Male and female subjects, aged between 21 and 59 inclusive
- Healthy individuals with no comorbidities or on regular medication
- BMI between 18.5-25 kg/m2
- Mild to moderate severity of eczema, which will also be determined using our questionnaires during screening visit
Key exclusion criteria (14 listed)
- Significant change in body weight (3 kg or more) in the past 3 months
- Significant exercise pattern over the past 3 months defined as high-intensity exercise of more than 3 hours per week
- Known food allergy to eggs
- Taking dietary supplements which may impact the study results
- Had been diagnosed or with a history of gastrointestinal disorders e.g. irritable bowel syndrome, constipation, diverticulitis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nutrients-fortified eggConsumption of 2 cooked nutrients fortified eggs (half-boiled, hard-boiled, or steamed) | Dietary supplement | Nutrients-fortified egg |
| Regular eggConsumption of 2 regular eggs, prepared in the same manner as nutrients-fortified egg, which serves as a placebo comparison. | Other | Regular egg |
Primary outcome
Change in eczema severity using the SCORing Atopic Dermatitis (SCORAD) index
Time frame: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
The SCORAD index is a validated composite scoring instrument designed to assess signs and symptoms of atopic dermatitis (AD). Total score ranges from 0 to 103, with higher scores indicating greater severity.
Change in eczema severity using the Eczema Area Severity Index (EASI)
Time frame: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
The EASI is a validated objective instrument for assessing signs of AD. Total score ranges from 0 to 72, with higher scores indicating greater severity.
Change in skin quality of life assessment using the Dermatology Life Quality Index (DLQI)
Time frame: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
The DLQI is a validated self-reported instrument assessing the self perception of impact of skin diseases on their quality of life over the previous week. Scores range from 0 to 30, with higher scores indicating greater impairment on quality of life.
Change in skin hydration level using corneometer
Time frame: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
A corneometer is an electronic device used to measure hydration on the skin surface
Change in transepidermal water loss level using tewameter
Time frame: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
A tewameter is an electronic device used to measure transepidermal water loss on the skin surface
Change in skin pH level using pH probe
Time frame: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
A pH probe is an electronic device used to measure pH levels on the skin surface
Change in skin sebum level using sebumeter
Time frame: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
A sebumeter is an electronic device used to measure sebum levels on the skin surface
Change in stratum corneum components via immune dot blot assay
Time frame: Baseline and Week 12
Outermost skin surface components will be extracted to conduct dot blot assays to assess changes during intervention period
Change in malondialdehyde level
Time frame: Every 6 weeks (Week 0, Week 6, Week 12)
Malondialdehyde concentration in blood samples will be measured
Change in 8-iso-prostaglandin F2α level
Time frame: Every 6 weeks (Week 0, Week 6, Week 12)
8-iso-prostaglandin F2α concentration in blood samples will be measured
Change in interleukin-6 level
Time frame: Every 6 weeks (Week 0, Week 6, Week 12)
Interleukin-6 concentration in blood samples will be measured
Change in tumor necrosis factor α
Time frame: Every 6 weeks (Week 0, Week 6, Week 12)
Tumor necrosis factor α concentration in blood samples will be measured
Change in fasting blood glucose level
Time frame: Every 6 weeks (Week 0, Week 6, Week 12)
Fasting glucose concentration in blood samples will be measured
Change in blood triglyceride level
Time frame: Every 6 weeks (Week 0, Week 6, Week 12)
Triglyceride concentration in blood samples will be measured
Change in blood total cholesterol level
Time frame: Every 6 weeks (Week 0, Week 6, Week 12)
Total cholesterol levels in blood samples will be measured
Change in blood Low-density Lipoprotein-cholesterol (LDL) level
Time frame: Every 6 weeks (Week 0, Week 6, Week 12)
LDL concentration in blood samples will be measured
Change in blood High-density Lipoprotein-cholesterol (HDL) level
Time frame: Every 6 weeks (Week 0, Week 6, Week 12)
HDL concentration in blood samples will be measured
9 secondary outcomes
Change in Blood Carotenoid levels using High Performance Liquid Chromatography (HPLC)
Time frame: Every 6 weeks (Week 0, Week 6, Week 12)
Change in Skin Carotenoid levels using BioPhotonic Scanner
Time frame: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
Change in Eye Carotenoid levels using Macular Pigment Scanner
Time frame: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
Change in Skin Advanced Glycation End-product (AGEs)
Time frame: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
Change in Blood AGEs
Time frame: Every 6 weeks (Week 0, Week 6, Week 12)
Change in Eye Visual Function using the NEI VFQ-25
Time frame: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
Change in Visual Acuity using eye chart
Time frame: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
Change in Contrast Sensitivity using eye chart
Time frame: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
Change in Photostress Recovery Time using eye chart
Time frame: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Nov 2023.
- Background: PubMed 29941810Ito N, Seki S, Ueda F. The Protective Role of Astaxanthin for UV-Induced Skin Deterioration in Healthy People-A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. 2018 Jun 25;10(7):817. doi: 10.3390/nu10070817.
- Derived from this study: PubMed 41417237Hu W, Li S, Li X, Chng ASM, Quek C, Chong Z, Khoo CM, Kim JE. Impact of antioxidants fortified eggs consumption on eye health in individuals with mild to moderate untreated eczema: a randomized controlled trial. Eur J Nutr. 2025 Dec 19;65(1):13. doi: 10.1007/s00394-025-03854-z.
- Individual participant dataSharing planned: No. Hard copy documents containing identifiable participant information will be stored in locked storage cabinets accessible only to members of the NUS research group. These locked storage cabinets are located in Kim lab in NUS. This lab is accessible only to Dr Kim Jung Eun, the Principal Investigator, and Dr Kim's research staff. The lab has a dual access security system, with the first entry point being an electronic lock accessible by an NUS-approved key card and the second is a physical lock. Electronic copies of the data with identifiable participant information stored electronically in NUS OneDrive. Only members of Dr Kim's lab have access to this secured folder. Access to this OneDrive folder is only granted by Dr Kim. All study samples will be de-identified prior to analysis and statistical analyses.
Related trials for Eczema, Atopic
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingPhase 1
A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis
Dermatitis Atopic
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jung Eun Kim, PhD principal investigator
Food Science and technology, Faculty of Science, National University of Singapore
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nutrients-fortified egg and Regular egg in people with Eczema, Atopic and Inflammation; Skin, run by National University of Singapore at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 9 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in eczema severity using the SCORing Atopic Dermatitis (SCORAD) index (time frame: Every 3 weeks (Week 0, Week 3, Week 6, Week 9, Week 12)). The study lists 17 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05913791, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Nov 2023.